BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38169111)

  • 21. Defects in the DNA mismatch repair system do not contribute to the development of childhood wilms tumors.
    Segers H; van den Heuvel-Eibrink MM; de Krijger RR; Pieters R; Wagner A; Dinjens WN
    Pediatr Dev Pathol; 2013; 16(1):14-9. PubMed ID: 23438691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
    Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
    Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.
    Astuti D; Morris MR; Cooper WN; Staals RH; Wake NC; Fews GA; Gill H; Gentle D; Shuib S; Ricketts CJ; Cole T; van Essen AJ; van Lingen RA; Neri G; Opitz JM; Rump P; Stolte-Dijkstra I; Müller F; Pruijn GJ; Latif F; Maher ER
    Nat Genet; 2012 Feb; 44(3):277-84. PubMed ID: 22306653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.
    Küry S; Ebstein F; Mollé A; Besnard T; Lee MK; Vignard V; Hery T; Nizon M; Mancini GMS; Giltay JC; Cogné B; McWalter K; Deb W; Mor-Shaked H; Li H; Schnur RE; Wentzensen IM; Denommé-Pichon AS; Fourgeux C; Verheijen FW; Faurie E; Schot R; Stevens CA; Smits DJ; Barr E; Sheffer R; Bernstein JA; Stimach CL; Kovitch E; Shashi V; Schoch K; Smith W; van Jaarsveld RH; Hurst ACE; Smith K; Baugh EH; Bohm SG; Vyhnálková E; Ryba L; Delnatte C; Neira J; Bonneau D; Toutain A; Rosenfeld JA; ; Audebert-Bellanger S; Gilbert-Dussardier B; Odent S; Laumonnier F; Berger SI; Smith ACM; Bourdeaut F; Stern MH; Redon R; Krüger E; Margueron R; Bézieau S; Poschmann J; Isidor B
    Am J Hum Genet; 2022 Feb; 109(2):361-372. PubMed ID: 35051358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer.
    Kuiper RP; Vreede L; Venkatachalam R; Ricketts C; Kamping E; Verwiel E; Govaerts L; Debiec-Rychter M; Lerut E; van Erp F; Hoogerbrugge N; van Kempen L; Schoenmakers EF; Bonne A; Maher ER; Geurts van Kessel A
    Cancer Genet Cytogenet; 2009 Dec; 195(2):105-11. PubMed ID: 19963109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Constitutional 560.49 kb chromosome 2p24.3 duplication including the MYCN gene identified by SNP chromosome microarray analysis in a child with multiple congenital anomalies and bilateral Wilms tumor.
    Micale MA; Embrey B; Macknis JK; Harper CE; Aughton DJ
    Eur J Med Genet; 2016 Dec; 59(12):618-623. PubMed ID: 27794475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1.
    Pontén E; Frisk S; Taylan F; Vaz R; Wessman S; de Kock L; Pal N; Foulkes WD; Lagerstedt-Robinson K; Nordgren A
    J Med Genet; 2022 Feb; 59(2):141-146. PubMed ID: 33208384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
    Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral Nephroblastic Tumors and a Complex Renal Vascular Anomaly in a Patient With a Mosaic RASopathy: Novel Histopathologic Features and Molecular Insights.
    Slack JC; Bründler MA; Chang CA; Perrier R; Lafay-Cousin L; Kurek KC
    Pediatr Dev Pathol; 2021; 24(3):235-240. PubMed ID: 33538228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.
    Drake KM; Ruteshouser EC; Natrajan R; Harbor P; Wegert J; Gessler M; Pritchard-Jones K; Grundy P; Dome J; Huff V; Jones C; Aldred MA
    Clin Cancer Res; 2009 Oct; 15(19):5985-92. PubMed ID: 19789318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation Statuses of H19DMR and KvDMR at WT2 in Wilms Tumors in Taiwan.
    Lu MY; Wang WC; Hou TC; Kuo CY; Lai YC
    Pathol Oncol Res; 2020 Oct; 26(4):2153-2159. PubMed ID: 32157637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Study of Human FBXW7 Deleterious nsSNP's Functional Inference and Susceptibility to Gynaecological Cancer.
    Vasuki KA; Christy HJ
    Appl Biochem Biotechnol; 2022 Jan; 194(1):407-433. PubMed ID: 34817806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contribution of WTAP gene variants to Wilms tumor susceptibility.
    Ma L; Hua RX; Lin H; Zhu J; Fu W; Lin A; Zhang J; Cheng J; Zhou H; Li S; Zhuo Z; He J
    Gene; 2020 Sep; 754():144839. PubMed ID: 32504654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WWOX Loss of Function in Neurodevelopmental and Neurodegenerative Disorders.
    Aldaz CM; Hussain T
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
    Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
    J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RASA1 inhibits the progression of renal cell carcinoma by decreasing the expression of miR-223-3p and promoting the expression of FBXW7.
    Zhang RL; Aimudula A; Dai JH; Bao YX
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32588875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.